Volume 179, Issue 1

Search all Psychopharmacology articles

April 2005

Glutamate Receptor Subtypes: Promising New Pharmacotherapeutic Targets

32 articles in this issue

Glutamate receptor subtypes: promising new pharmacotherapeutic targets
Guy A. Higgins
Klaus A. Miczek
Editorial 11 March 2005 Pages: 1 - 3
Ionotropic and metabotropic glutamate receptor structure and pharmacology
James N. C. Kew
John A. Kemp
Review 25 February 2005 Pages: 4 - 29
N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives
Mark J. Millan
Review 10 March 2005 Pages: 30 - 53
Modulators of the glycine site on NMDA receptors, d-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia
Tatiana Lipina
Viviane Labrie
John Roder
Original Investigation 10 March 2005 Pages: 54 - 67
Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGLU_2/3 receptor agonist LY379268
Barbara Greco
Roberto W. Invernizzi
Mirjana Carli
Original Investigation 28 January 2005 Pages: 68 - 76
Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia
Alice Egerton
Lee Reid
Judith A. Pratt
Original Investigation 29 January 2005 Pages: 77 - 84
Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat
Guy A. Higgins
Theresa M. Ballard
John A. Kemp
Original Investigation 10 March 2005 Pages: 85 - 98
Local glutamate receptor antagonism in the rat prefrontal cortex disrupts response inhibition in a visuospatial attentional task
Emily R. Murphy
Jeffrey W. Dalley
Trevor W. Robbins
Original Investigation 28 January 2005 Pages: 99 - 107
Co-activation of glutamate and dopamine receptors within the nucleus accumbens is required for spatial memory consolidation in mice
Valentina Ferretti
Cédrick Florian
Andrea Mele
Original Investigation 29 January 2005 Pages: 108 - 116
Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson’s disease
Nathalie Turle-Lorenzo
Nathalie Breysse
Marianne Amalric
Original Investigation 22 February 2005 Pages: 117 - 127
Drug discrimination analysis of NMDA receptor channel blockers as nicotinic receptor antagonists in rats
E. S. Zakharova
W. Danysz
A. Y. Bespalov
Original Investigation 29 January 2005 Pages: 128 - 135
Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine
Hyun-Sang Cho
Deepak C. D’Souza
John H. Krystal
Original Investigation 29 January 2005 Pages: 136 - 143
A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients
Donald C. Goff
Lawrence Herz
David Schoenfeld
Original Investigation 21 October 2004 Pages: 144 - 150
Pouring oil into the fire? On the conundrum of the beneficial effects of NMDA receptor antagonists in Alzheimer disease
H. Peter Schmitt
Commentary 24 December 2004 Pages: 151 - 153
Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data
Mark D. Black
Review 26 January 2005 Pages: 154 - 163
Effects of deletion of gria1 or gria2 genes encoding glutamatergic AMPA-receptor subunits on place preference conditioning in mice
Andy N. Mead
Geraldine Brown
David N. Stephens
Original Investigation 24 December 2004 Pages: 164 - 171
Repeated administration of AMPA or a metabotropic glutamate receptor agonist into the rat ventral tegmental area augments the subsequent behavioral hyperactivity induced by cocaine
Justin M. Dunn
Brian R. Inderwies
R. Christopher Pierce
Original Investigation 04 December 2004 Pages: 172 - 180
Locomotor activity detects subunit-selective effects of agonists and decahydroisoquinoline antagonists at AMPA/kainic acid ionotropic glutamate receptors in adult rats
Michael F. O’Neill
Graham Sanger
Sandra M. Woodhouse
Original Investigation 26 January 2005 Pages: 181 - 188
NMDA or AMPA/kainate receptor blockade prevents acquisition of conditioned place preference induced by D_2/3 dopamine receptor stimulation in rats
Anna-Maria Biondo
Robert L. H. Clements
Andrew J. Greenshaw
Original Investigation 03 March 2005 Pages: 189 - 197
Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test
Thomas Steckler
Hilde Lavreysen
Anne S. J. Lesage
Original Investigation 04 December 2004 Pages: 198 - 206
The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles
Geoffrey B. Varty
Mariagrazia Grilli
Rosalia Bertorelli
Original Investigation 29 January 2005 Pages: 207 - 217
The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison
Theresa M. Ballard
Marie L. Woolley
Will Spooren
Original Investigation 01 March 2005 Pages: 218 - 229
Behavioral sensitization due to social defeat stress in mice: antagonism at mGluR5 and NMDA receptors
Jasmine J. Yap
Herbert E. Covington III
Klaus A. Miczek
Original Investigation 23 October 2004 Pages: 230 - 239
Blockade of the mGlu5 receptor decreases basal and stress-induced cortical norepinephrine in rodents
Michelle E. Page
Paul Szeliga
John F. Cryan
Original Investigation 17 February 2005 Pages: 240 - 246
Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats
Paul J. Kenny
Benjamin Boutrel
Athina Markou
Original Investigation 16 December 2004 Pages: 247 - 254
The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats
Neil E. Paterson
Athina Markou
Original Investigation 24 December 2004 Pages: 255 - 261
The mGluR5 antagonist MPEP decreases operant ethanol self-administration during maintenance and after repeated alcohol deprivations in alcohol-preferring (P) rats
Jason P. Schroeder
David H. Overstreet
Clyde W. Hodge
Original Investigation 17 February 2005 Pages: 262 - 270
Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)
Michael P. Johnson
David Barda
Darryle D. Schoepp
Original Investigation 17 February 2005 Pages: 271 - 283
Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice
A.-M. Linden
H. Shannon
D. D. Schoepp
Original Investigation 24 December 2004 Pages: 284 - 291
Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys
Simona Spinelli
Theresa Ballard
Christopher R. Pryce
Original Investigation 28 January 2005 Pages: 292 - 302
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects
John H. Krystal
Walid Abi-Saab
Alan Breier
Original Investigation 10 August 2004 Pages: 303 - 309
Effects of a metabotropic glutamate_2/3 receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results
Michael Kellner
Christoph Muhtz
Klaus Wiedemann
Original Investigation 30 September 2004 Pages: 310 - 315

Volume 179, Issue 1

Glutamate receptor subtypes: promising new pharmacotherapeutic targets

Ionotropic and metabotropic glutamate receptor structure and pharmacology

N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives

Modulators of the glycine site on NMDA receptors, d-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia

Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGLU_2/3 receptor agonist LY379268

Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia

Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat

Local glutamate receptor antagonism in the rat prefrontal cortex disrupts response inhibition in a visuospatial attentional task

Co-activation of glutamate and dopamine receptors within the nucleus accumbens is required for spatial memory consolidation in mice

Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson’s disease

Drug discrimination analysis of NMDA receptor channel blockers as nicotinic receptor antagonists in rats

Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine

A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients

Pouring oil into the fire? On the conundrum of the beneficial effects of NMDA receptor antagonists in Alzheimer disease

Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data

Effects of deletion of gria1 or gria2 genes encoding glutamatergic AMPA-receptor subunits on place preference conditioning in mice

Repeated administration of AMPA or a metabotropic glutamate receptor agonist into the rat ventral tegmental area augments the subsequent behavioral hyperactivity induced by cocaine

Locomotor activity detects subunit-selective effects of agonists and decahydroisoquinoline antagonists at AMPA/kainic acid ionotropic glutamate receptors in adult rats

NMDA or AMPA/kainate receptor blockade prevents acquisition of conditioned place preference induced by D_2/3 dopamine receptor stimulation in rats

Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test

The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles

The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison

Behavioral sensitization due to social defeat stress in mice: antagonism at mGluR5 and NMDA receptors

Blockade of the mGlu5 receptor decreases basal and stress-induced cortical norepinephrine in rodents

Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats

The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats

The mGluR5 antagonist MPEP decreases operant ethanol self-administration during maintenance and after repeated alcohol deprivations in alcohol-preferring (P) rats

Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)

Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice

Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

Effects of a metabotropic glutamate_2/3 receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results

Navigation